Patrick J. Loehrer
Patrick J. Loehrer | |
|---|---|
| Born | 1952 (age 71–72) |
| Alma mater |
|
| Scientific career | |
| Institutions | |
| Website | cancer |
Patrick J. Loehrer is an American oncologist who is Indiana University Distinguished Professor, Joseph W. and Jackie J. Cusick Professor in Oncology, Professor of medicine, Indiana University School of Medicine; Director emeritus, Indiana University Melvin and Bren Simon Comprehensive Cancer Center.[1]
Career
[edit]Along with Lawrence Einhorn, Kenneth Pennington, Rafat Ansari, Prasad Mantravadi, and William B. Fisher, in 1984, he co-founded the Hoosier Oncology Group.[2]
In 2002, he became Director of the Division of Hematology/Oncology at Indiana University School of Medicine.[3]
Loehrer was director of the Indiana University Melvin and Bren Simon Comprehensive Cancer Center from 2010-2021. He succeeded Steve Williams who was the founding director of the NCI designated center at the time of its designation in 1999. As Director, Loehrer worked to build the NCI designated cancer center, ultimately leading to NCI designation as a Comprehensive Cancer Center in 2019.[4] He was director until January 2021 when he was succeeded by Kelvin Lee.[5] Loehrer is a member of the Experimental and Developmental Therapeutics Program at the IU Simon Comprehensive Cancer Center.
He founded the Academic Model Providing Access to Healthcare (AMPATH)-Oncology Program, a partnership of North American institutions with Moi University and Moi Teaching and Referral Hospital in Kenya.[6]
More recently, he has hosted the Oncology, Etc., an American Society of Clinical Oncology podcast, with David Johnson.[7]
Research
[edit]Loehrer has made notable contributions to research in the care of patients with colorectal cancer,[8] germ cell tumor,[9] pancreatic cancer,[10] bladder cancer,[11] and thymic epithelial tumors.[12]
Awards and honors
[edit]- In 2021, he received The Big Ten Cancer Research Consortium Institutional Leadership Award and the inaugural Pat Loehrer Award for Exemplary Collaboration in Cancer Research[13]
- In 2017, he received the Allen S. Lichter Visionary Leader Award and Lecture from the American Society of Clinical Oncology. This award recognizes a recipient who has drastically changed the oncology field or who has made significant contributions to advance the mission of the American Society of Clinical Oncology through the honoree's ability to lead and inspire.[14]
- In 2015, he received the Purdue University College of Engineering 2015 Distinguished Engineering Alumni award "for lifesaving cancer research and achievements demonstrating that Purdue engineering alumni and alumnae can become world-renowned leaders in any field and make highly significant impacts on human lives."[15]
References
[edit]- ^ "Patrick J. Loehrer". The Cancer Letter. Retrieved 22 June 2022.
- ^ "Our Story". Hoosier Cancer Research Network.
- ^ "Patrick J. Loehrer: University Honors and Awards: Indiana University". University Honors & Awards.
- ^ "Indiana University Simon Cancer Center becomes 51st NCI-designated comprehensive cancer center". The Cancer Letter. 6 August 2019.
- ^ "Indiana University Melvin and Bren Simon Comprehensive Cancer Center becomes 51st NCI-designated comprehensive cancer center". The Cancer Letter. 6 August 2019.
- ^ November 25, ASCO. "ASCO President-Elect Candidates Discuss Key Issues in Oncology - The ASCO Post". ascopost.com.
{{cite web}}: CS1 maint: numeric names: authors list (link) - ^ "ASCO". education.asco.org.
- ^ Saltz, Leonard B.; Meropol, Neal J.; Loehrer, Patrick J.; Needle, Michael N.; Kopit, Justin; Mayer, Robert J. (1 April 2004). "Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor". Journal of Clinical Oncology. 22 (7): 1201–1208. doi:10.1200/JCO.2004.10.182. ISSN 0732-183X. PMID 14993230.
- ^ Williams, Stephen D.; Birch, Robert; Einhorn, Lawrence H.; Irwin, Linda; Greco, F. Anthony; Loehrer, Patrick J. (4 June 1987). "Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or Etoposide". New England Journal of Medicine. 316 (23): 1435–1440. doi:10.1056/NEJM198706043162302. ISSN 0028-4793. PMID 2437455.
- ^ Loehrer, Patrick J.; Feng, Yang; Cardenes, Higinia; Wagner, Lynne; Brell, Joanna M.; Cella, David; Flynn, Patrick; Ramanathan, Ramesh K.; Crane, Christopher H.; Alberts, Steven R.; Benson, Al B. (1 November 2011). "Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial". Journal of Clinical Oncology. 29 (31): 4105–4112. doi:10.1200/JCO.2011.34.8904. ISSN 0732-183X. PMC 3525836. PMID 21969502.
- ^ Loehrer, P. J.; Einhorn, L. H.; Elson, P. J.; Crawford, E. D.; Kuebler, P.; Tannock, I.; Raghavan, D.; Stuart-Harris, R.; Sarosdy, M. F.; Lowe, B. A. (July 1992). "A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study". Journal of Clinical Oncology. 10 (7): 1066–1073. doi:10.1200/JCO.1992.10.7.1066. ISSN 0732-183X. PMID 1607913.
- ^ Loehrer, P J; Kim, K; Aisner, S C; Livingston, R; Einhorn, L H; Johnson, D; Blum, R (1 June 1994). "Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group". Journal of Clinical Oncology. 12 (6): 1164–1168. doi:10.1200/JCO.1994.12.6.1164. ISSN 0732-183X. PMID 8201378.
- ^ "Loehrer and IU Simon Comprehensive Cancer Center honored during Summit". Big Ten Cancer Research Consortium. 8 January 2021.
- ^ "The ASCO Post". ascopost.com.
- ^ "Patrick Loehrer". College of Engineering - Purdue University.
External links
[edit]| International | |
|---|---|
| National | |
| Academics | |
